Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Common Equity (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Common Equity for 3 consecutive years, with $305.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 34.08% to $305.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $305.7 million through Dec 2025, down 34.08% year-over-year, with the annual reading at $305.7 million for FY2025, 34.08% down from the prior year.
  • Common Equity for Q4 2025 was $305.7 million at Nuvation Bio, down from $325.9 million in the prior quarter.
  • The five-year high for Common Equity was $641.1 million in Q1 2023, with the low at $257.2 million in Q2 2024.
  • Average Common Equity over 3 years is $477.0 million, with a median of $483.3 million recorded in 2024.
  • The sharpest move saw Common Equity crashed 58.82% in 2024, then soared 44.99% in 2025.
  • Over 3 years, Common Equity stood at $605.1 million in 2023, then decreased by 23.36% to $463.8 million in 2024, then plummeted by 34.08% to $305.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $305.7 million, $325.9 million, and $372.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.